A CRA expert was retained to analyze class certification issues relating to allegations that a pharmaceutical product was marketed for off-label uses and caused direct and indirect purchasers to pay for billions of dollars unnecessarily. The expert found that differences among putative class members would necessitate individualized inquiries into whether the alleged conduct caused each any economic damages. The judge denied class certification, citing the CRA expert’s opinion in support of several key points.
Andy Baziliauskas and Margaret Sanderson awarded the Bill Miller Memorial Award
Andy Baziliauskas and Margaret Sanderson were recognized at the 2024 Canadian Bar Association Competition Law Spring Conference for addressing an important...